Quark SEC Filing Provides New Details on Company Pipeline, Financials
October 07, 2010
Quark SEC Filing Provides New Details on Company Pipeline, Financials
The Israeli firm said that it intends to file two investigational new drug applications, one from its stable of in-house drug candidates and one from a collaboration with Japan's Nitto Denko, in 2012.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Quark Scuttles IPO Plans for the Second Time
September 29, 2011 / Gene Silencing News - Still Eyeing IPO, Quark Says Cost Expectations for Rx Pipeline Exceed $54M
January 27, 2011 / Gene Silencing News - Quark to Run Phase IIa Trial of RNAi Drug in Glaucoma
May 3, 2012 / Gene Silencing News - Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News - Quark Still Sees IPO as a Possibility as Phase II Trials Near Completion
February 9, 2012 / Gene Silencing News